Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EBITDA: 2022-2025

Historic EBITDA for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$15.3 million.

  • Phathom Pharmaceuticals' EBITDA rose 78.43% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.5 million, marking a year-over-year increase of 25.86%. This contributed to the annual value of -$277.5 million for FY2024, which is 65.84% down from last year.
  • Phathom Pharmaceuticals' EBITDA amounted to -$15.3 million in Q3 2025, which was up 74.52% from -$59.9 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' EBITDA registered a high of -$15.3 million during Q3 2025, and its lowest value of -$78.9 million during Q1 2025.
  • Over the past 3 years, Phathom Pharmaceuticals' median EBITDA value was -$59.9 million (recorded in 2025), while the average stood at -$54.4 million.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' EBITDA slumped by 143.84% in 2024, and later skyrocketed by 78.43% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' EBITDA (Quarterly) stood at -$46.6 million in 2022, then crashed by 49.81% to -$69.9 million in 2023, then increased by 14.97% to -$59.4 million in 2024, then skyrocketed by 78.43% to -$15.3 million in 2025.
  • Its last three reported values are -$15.3 million in Q3 2025, -$59.9 million for Q2 2025, and -$78.9 million during Q1 2025.